JNJ

186.77

-1.86%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

JNJ

186.77

-1.86%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

JNJ

186.77

-1.86%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

JNJ

186.77

-1.86%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

JNJ

186.77

-1.86%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

Search

Abbott Laboratories

Gesloten

SectorGezondheidszorg

126.59 -0.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

126.17

Max

128.44

Belangrijke statistieken

By Trading Economics

Inkomsten

454M

1.8B

Verkoop

227M

11B

K/W

Sectorgemiddelde

16.128

37.461

EPS

1.3

Dividendrendement

1.84

Winstmarge

15.967

Werknemers

114,000

EBITDA

-824M

2.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+15.69% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.84%

2.33%

Volgende dividenddatum

17 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-3.3B

225B

Vorige openingsprijs

127.03

Vorige sluitingsprijs

126.59

Nieuwssentiment

By Acuity

55%

45%

314 / 373 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Abbott Laboratories Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 okt 2025, 12:02 UTC

Winsten

Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook

17 jul 2025, 12:10 UTC

Winsten

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

22 okt 2025, 19:57 UTC

Acquisities, Fusies, Overnames

Synlait Milk Ltd.: OIO Gives Abbott Consent to Acquire Co's North Island Assets

15 okt 2025, 16:15 UTC

Winsten

Abbott Stock Drops Despite Earnings. Baby-Formula Sales Took a Hit. -- Barrons.com

15 okt 2025, 12:25 UTC

Winsten

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway. -- Barrons.com

15 okt 2025, 11:32 UTC

Winsten

Abbott Labs Still Sees 2025 Organic Sales Up 6%-7% Including Covid-19 Testing-Related Sales >ABT

15 okt 2025, 11:32 UTC

Winsten

Abbott Labs Still Sees 2025 Organic Sales Up 7.5%-8% Excluding Covid-19 Testing-Related Sales >ABT

15 okt 2025, 11:31 UTC

Winsten

Abbott Labs Sees 2025 Adj EPS $5.12-Adj EPS $5.18 >ABT

15 okt 2025, 11:30 UTC

Winsten

Abbott Labs 3Q Adjusted Operating Margin 23% >ABT

15 okt 2025, 11:30 UTC

Winsten

Abbott Labs Reaffirms Full-Year Guidance >ABT

15 okt 2025, 11:30 UTC

Winsten

Abbott Labs 3Q Organic Sales Growth Up 5.5% >ABT

15 okt 2025, 11:30 UTC

Winsten

Abbott Labs 3Q Sales $11.37B >ABT

15 okt 2025, 11:30 UTC

Winsten

Abbott Labs 3Q Adj EPS $1.30 >ABT

15 okt 2025, 11:30 UTC

Winsten

Abbott Labs 3Q Net $1.64B >ABT

15 okt 2025, 11:30 UTC

Winsten

Abbott Labs 3Q EPS 94c >ABT

11 okt 2025, 00:18 UTC

Acquisities, Fusies, Overnames

Why Biotech May Be Back -- Barrons.com

17 jul 2025, 13:14 UTC

Winsten

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 jul 2025, 12:16 UTC

Winsten

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 jul 2025, 11:32 UTC

Winsten

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17 jul 2025, 11:32 UTC

Winsten

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17 jul 2025, 11:31 UTC

Winsten

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Sales $11.14B >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Net $1.78B >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q Adj EPS $1.26 >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17 jul 2025, 11:30 UTC

Winsten

Abbott Labs 2Q EPS $1.01 >ABT

Peer Vergelijking

Prijswijziging

Abbott Laboratories Prognose

Koersdoel

By TipRanks

15.69% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 147.13 USD  15.69%

Hoogste 162 USD

Laagste 136 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Abbott Laboratories - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

17

Buy

2

Hold

0

Sell

Technische score

By Trading Central

132.82 / 134.43Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

314 / 373 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat